

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VISEN Pharmaceuticals
维昇药业
(incorporated in the Cayman Islands with limited liability)
(Stock code: 2561)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

The board of directors (the “**Board**”) of VISEN Pharmaceuticals (the “**Company**”) is pleased to announce that the resolutions (the “**Resolutions**”) as set out in the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) was duly passed as ordinary resolutions by the Independent Shareholders by way of poll at the EGM held on April 22, 2026. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the Notice and the circular of the Company dated March 26, 2026 (the “**Circular**”).

Full text of the Resolutions is set out in the Notice, a copy of which is set out in the Circular. The poll result is as follows:

ORDINARY RESOLUTIONS		Number of votes (%)		
		For	Against	Abstain
1.	To generally and unconditionally approve, confirm and ratify the Exclusive Licence Framework Agreement entered into between the Company and the ELA Ascendis Subsidiaries on March 26, 2026, the Revised 2026 ELA Annual Cap, the ELA Future Annual Caps and the transaction contemplated thereunder, and to authorize the directors of the Company acting together or by committee, or any director of the Company acting individually, to do all such further acts and things and execute such further documents and take all such steps which in his/her/their opinion may be necessary, desirable or expedient to implement and/or give effect to the terms of such continuing connected transactions.	44,502,379 (99.942712%)	0 0.000000%	25,509 (0.057288%)

ORDINARY RESOLUTIONS		Number of votes (%)		
		For	Against	Abstain
2.	To generally and unconditionally approve, confirm and ratify the 1st Commercial Supply Framework Agreement entered into between VISEN HK and Ascendis Pharma Endocrinology Division on March 26, 2026, the Revised 2026 CSA Annual Cap and CSA Future Annual Cap and the transaction contemplated thereunder, and to authorize the directors of the Company acting together or by committee, or any director of the Company acting individually, be and is hereby authorised to do all such further acts and things and execute such further documents and take all such steps which in his/her/their opinion may be necessary, desirable or expedient to implement and/or give effect to the terms of such continuing connected transactions.	44,502,379 (99.942712%)	0 0.000000%	25,509 (0.057288%)
3.	To generally and unconditionally approve, confirm and ratify the supplemental agreement to the 2nd Commercial Supply Framework Agreement entered into between VISEN HK and Ascendis Europe on March 26, 2026 and the Revised 2nd CSFA Annual Caps and to authorize the directors of the Company acting together or by committee, or any director of the Company acting individually, be and is hereby authorised to do all such further acts and things and execute such further documents and take all such steps which in his/her/their opinion may be necessary, desirable or expedient to implement and/or give effect to the terms of such continuing connected transactions.	44,502,379 (99.942712%)	0 0.000000%	25,509 (0.057288%)

Notes:

- (1) *As at the date of the EGM, there were a total of 113,926,864 Shares in issue.*
- (2) *Pursuant to Rule 14A.36 of the Listing Rules, any Shareholder who has a material interest in the connected transaction must abstain from voting on the relevant resolution at the EGM. As such, The Ascendis Subsidiaries, each being a controlling shareholder of the Company holding an aggregate of 41,136,364 Shares, representing approximately 36.11% of the issued Shares, as at the date of the EGM, was required to abstain, and had abstained, from voting at the EGM in respect of the Resolutions at the EGM. Apart from the Ascendis Subsidiaries, the Company was not aware of any other Shareholder that was required to abstain from voting on the Resolutions.*

- (3) *There were 72,790,500 Shares, representing approximately 63.89 % of the issued Shares, entitling the Independent Shareholders to attend and vote on the Resolution at the EGM. Tricor Trust (Hong Kong) Limited, being the trustee holding 3,058,000 unvested RSUs granted under the Equity Incentive Plan; and Tricor Equity Trustee Limited being the trustee holding 1,500,000 Shares underlying RSUs granted to Mr. Lu under the Equity Incentive Plan, was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules.*
- (4) *The number of votes and percentage of voting as stated above are based on the total number of the issued Shares held by the Independent Shareholders who attended and actually voted at the EGM in person or by authorised corporate representative(s) or by proxy(ies).*
- (5) *As more than 50% of the votes were cast in favour of the Resolutions, the Resolutions were duly passed as ordinary resolutions.*
- (6) *There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the Resolution at the EGM as set out in Rule 13.40 of the Listing Rules.*
- (7) *None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the Resolution at the EGM.*
- (8) *The Hong Kong Branch share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for vote-taking at the EGM.*
- (9) *All Directors attended the EGM either in person or by electronic means.*

On behalf of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, April 22, 2026

As at the date of this announcement, the Board comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.